Latest SEC filings for Moderna, Inc. (MRNA) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Moderna, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Bancel Stephane (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Hoge Stephen (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme, listed as Chief Legal Officer at Moderna, Inc., reported an open-market sale of 13,885 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Hoge Stephen, listed as President at Moderna, Inc., reported an open-market sale of 160,009 MRNA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Hoge Stephen filed a Form 144 with the SEC indicating intent to sell MRNA (Moderna, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.
Moderna, Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.
Mock James M (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Klinger Shannon Thyme (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Hoge Stephen (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.